Sunshine Biopharma INC Schedule 13G passive stakes

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have filed an amended Schedule 13G, reporting beneficial ownership of 9.99% of Sunshine Biopharma Inc. common stock.

Alta Partners LLC has reported beneficial ownership of 200,000 shares, representing 8.6% of the outstanding common stock of Sunshine Biopharma Inc., acquired through warrant exercises.

L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G reporting a 5.83% beneficial ownership stake in Sunshine Biopharma Inc.

Several investment entities and Michael Bigger have reported their beneficial ownership of Sunshine Biopharma Inc. common stock, with a combined stake of 9.47% as of May 18, 2025.

Altium Capital Management LLC and its affiliates have reported a 0% beneficial ownership in Sunshine Biopharma, Inc. common stock, indicating a full divestment of their previous holdings.

Bigger Capital Fund L P, Bigger Capital Fund GP, LLC, and Michael Bigger have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Sunshine Biopharma Inc. common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 9.99% in Sunshine Biopharma Inc. through a Schedule 13G filing.

Bigger Capital Fund L P, Bigger Capital Fund GP, LLC, and Michael Bigger have jointly disclosed a beneficial ownership of 8.17% in Sunshine Biopharma Inc.'s common stock as of April 2, 2025.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amendment to its Schedule 13G, reporting a 4.99% beneficial ownership stake in Sunshine Biopharma Inc., primarily through Series B Warrants subject to a beneficial ownership limitation.